Table of ContentsView AllTable of ContentsDMT vs. Symptom ManagementInjectable DMTsOral DMTsInfused DMTsFrequently Asked Questions
Table of ContentsView All
View All
Table of Contents
DMT vs. Symptom Management
Injectable DMTs
Oral DMTs
Infused DMTs
Frequently Asked Questions
Inmultiple sclerosis (MS), a person’s immune system attacks the protective covering (myelin sheath) of nerve fibers in the brain and spinal cord (central nervous system). MS disease-modifying therapies (DMTs) are medications that disrupt these misguided attacks. DMTs are available in three different forms—injections, oral therapies, andIV infusions.
Most are approved to treat relapsing forms of MS in adults. This includesrelapsing-remitting MS(the most common form, with periods of symptom relapses and remissions), activesecondary progressive MS(with steadily worsening symptoms and few or no remissions), andclinically isolated syndrome(one neurological event with symptoms and signs of MS).
This article will compare the numerous DMT options available, including their unique side effect profiles.
The Good Brigade / Getty Images
DMTs are drugs to improve the long-term outlook of the condition. They reduce the number and severity ofMS relapsesand slow down the natural progression of the disease.
Starting a DMT Soon After DiagnosisResearch indicates that early treatment with DMTs plays a key role in delaying disability and disease progression.
Starting a DMT Soon After Diagnosis
Research indicates that early treatment with DMTs plays a key role in delaying disability and disease progression.
DMTs are not used to treat individual relapses or daily MS symptoms.
Moderate to severe MS relapses are typically treated with a high-dose, anti-inflammatorycorticosteroidlikeSolu-Medrol (methylprednisolone)or prednisone.
Thesymptoms of MS, like fatigue, bladder dysfunction, pain, and walking problems, are treated with various symptom-targeted medications and/or rehabilitation therapies.
How Multiple Sclerosis Is Treated
Injectable DMTs are given as a shot either into one of your muscles (intramuscular) or beneath your skin (subcutaneous).
Beta Interferon Drugs
Interferons are proteins that your body makes naturally to help regulate your immune system.
Beta interferon drugs are used to treat relapsing forms of MS. They include:
How They Are Taken
Administration of these drugs includes:
Side Effects
Common side effects of beta interferon drugs include:
BetaseronandExtaviamay also cause a lowwhite blood cell count. This can make you more vulnerable to infection.
Skin breakdown (damage to the skin’s surface) at the injection site, trouble sleeping, belly pain, andincreased liver enzymes(seen on a blood test) may also occur withBetaseronandExtavia.
Potential serious side effects of all the beta interferon drugs include liver failure and mental health problems, includingdepressionor suicidal thoughts.
Some of the drugs may also cause heart and blood vessel problems, seizures, and skin tissue death (necrosis).
Copaxone, Glatopa
CopaxoneandGlatopa(glatiramer acetate) are also injectable drugs.They block your immune system from attacking the protective myelin sheath covering of nerves and are used to treat relapsing forms of MS in adults.
CopaxoneandGlatopaare injected subcutaneously either every day or every three days (a higher dose is used).
The most common side effects associated withCopaxoneandGlatopaare redness, pain, and swelling at the injection site, along with flushing, trouble breathing, rash, and chest pain.
Potential serious side effects include skin necrosis, lipoatrophy (loss of fatty tissue beneath the skin), and liver failure.
Oral DMTs may be a reasonable choice for patients who prefer to take a pill rather than undergoing injections or infusions.
Gilenya and Tascenso ODT
Gilenya and Tascenso ODTare approved to treat relapsing forms of multiple sclerosis (MS) in adults.
First Pediatric DMT ApprovalGilenya and Tascenso ODT are also approved to treat children and adolescents with relapsing MS who are 10 years of age and older.
First Pediatric DMT Approval
Gilenya and Tascenso ODT are also approved to treat children and adolescents with relapsing MS who are 10 years of age and older.
How It’s Taken
Tascenso ODTis taken once daily, placed under the tongue to dissolve before swallowing, and taken with or without food.
GilenyaandTascenso ODTcan slow your heartbeat, especially when you first start it. As a result, you will have anelectrocardiogram (ECG)before you take your first dose. A healthcare professional will also monitor you for at least six hours after your first dose.
The most common side effects ofGilenyaandTascenso ODTare headache, abnormal liver tests, diarrhea, cough, flu, inflammation of the sinuses (sinusitis), and pain in your back, abdomen, arms, or legs.
Potential serious side effects include:
A vision problem calledmacular edemaand a condition called posterior reversible encephalopathy syndrome (PRES) where the blood vessels in your brain become swollen and narrowed may also occur.
Mayzent and Zeposia
Mayzent (siponimod) and Zeposia (Ozanimod) work similarly to Gilenya and are approved to treat relapsing forms of MS in adults.
How They’re Taken
WithZeposia(to prevent increasing your blood pressure), you will be asked to avoid meals or snacks that are high in tyramine like aged, fermented, cured, smoked, and pickled foods.
MayzentandZeposiamay slow your heart rate when you start taking it. As with Gilenya, an ECG is required before your first dose.
The most common side effects ofMayzentare headache,high blood pressure, and abnormal liver tests.
Potential serious side effects include life-threatening infections, macular edema, PRES, liver and breathing problems, severe worsening of your MS after stopping the drug, basal cell carcinoma, and melanoma.
WithZeposia, the most common side effects are:
Potential serious side effects ofZeposiainclude life-threatening infections, macular edema, PRES, liver and breathing problems, and severe worsening of your MS after stopping the drug.
Tecfidera
Tecfidera(dimethyl fumarate) is approved to treat relapsing forms of MS in adults.Tecfiderais believed to have anti-inflammatory and antioxidant properties that help protect against damage to the brain and spinal cord.
The most common side effects ofTecfideraare flushing, redness, itching, rash, nausea, vomiting, diarrhea, stomach pain, and indigestion.
Potential serious side effects include allergic reactions, PML, a lowering of your white blood cell count, liver problems, herpes zoster infection (shingles), and other serious infections.
Vumerity
Vumerity(diroximel fumarate) is similar to Tecfidera but has been found to be better tolerated, especially when it comes to gastrointestinal side effects. Like Tecfidera,Vumerityis approved to treat relapsing forms of MS in adults.
The most common side effects ofVumerityare flushing, redness, itching, or rash and stomach problems, including nausea, vomiting, diarrhea, pain, or indigestion.
Potential serious side effects include allergic reactions, PML, a lowering of your white blood cell count, liver problems, shingles, and other serious infections.
Bafiertam
Bafiertam(monomethyl fumarate) is similar to Tecfidera and Vumerity and is approved to treat relapsing forms of MS in adults.
The most common side effects ofBafiertamare flushing, redness, itching or rash, nausea, vomiting, diarrhea, stomach pain, or indigestion.
Aubagio
Aubagio(teriflunomide) blocks the function of certain immune system cells involved in MS and is used to treat relapsing forms of MS in adults.
Aubagiois taken once a day with or without food.
The most common side effects ofAubagioare headache, diarrhea, nausea, hair thinning or loss (alopecia), and abnormal liver blood tests.
Mavenclad
Mavenclad(cladribine) temporarily reduces the number ofT and B lymphocytes(types of white blood cells involved in immune reactions) in your body.Mavencladis approved to treat relapsing-remitting MS and active secondary progressive disease in adults.
Due to safety concerns, it’s generally recommended only for patients who cannot tolerate or who do not respond to other DMTs.
The most common side effects ofMavencladare upper respiratory infections, headache, and low white blood cell counts.
Infused DMTs are given through a needle placed in your vein at a healthcare facility,such as a doctor’s office, hospital, or infusion center.
Lemtrada
Lemtrada(alemtuzumab) is amonoclonal antibodythat targets a protein on the surface of immune system cells called CD52.Lemtradais approved to treat relapsing-remitting MS and active secondary progressive disease in adults.
Due to safety concerns, the FDA recommends this drug be reserved for patients who do not respond to two or more other DMTs.
Intravenous infusion ofLemtradais done over two or more treatment courses. You will receive the drug for five days in a row for the first treatment course and then for three days in a row about one year later.
Lemtradacarries numerous potential side effects.
Common ones include:
Potential serious side effects ofLemtradainclude:
Novantrone
Novantroneis approved to treat secondary progressive MS,progressive-relapsing MS, and worsening relapsing-remitting MS in adults.
Novantroneis infused every three months. Of note, there is a lifetime total allowed dose limit of around 10 doses over two to three years.
The most common side effects of Novantrone are:
Tyruko, Tysabri
TyrukoandTysabri(natalizumab) are monoclonal antibodies that help prevent potentially harmful immune system cells from crossing theblood-brain barrierinto the central nervous system.TyrukoandTysabriare approved for the treatment of relapsing forms of MS in adults.
TyrukoandTysabriare infused once every four weeks.
The most common side effects ofTyrukoandTysabriare:
TyrukoandTysabriinclude aboxed warningdue to the increased risk of developing PML. Other possible serious side effects include PML, herpes infections, liver damage, allergic reactions, weakened immune system, a higher risk of infections, and lowplateletcounts.
Ocrevus
Ocrevus(ocrelizumab) is a monoclonal antibody that targets a specific type of white blood cell—CD20 positive B lymphocytes.Ocrevusis approved to treat relapsing forms of MS in adults and also approved to treatprimary progressive MS (PPMS)in adults.
Ocrevusis infused once every six months.
The most common side effects ofOcrevusfor those with relapsing MS are upper respiratory tract infections and infusion reactions.
The most common side effects ofOcrevusfor those with PPMS are upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory infections.
Potential serious side effects include severe infusion reactions, infections (e.g., herpes viral, PML, and reactivation of hepatitis B), weakened immune system, and risk of cancer, includingbreast cancer.
Briumvi
Briumvi(ublituximab) is a monoclonal antibody that targets CD20-positive lymphocytes.Briumviis approved for the treatment of relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
Briumviis infused once every other week for the first treatment course and then once every six months thereafter.
The most common side effects ofBriumviare upper and lower respiratory tract infections, infusion reactions, and herpes infections.
Potential serious side effects include severe infusion reactions and infections (e.g., herpes virus, PML, and reactivation of hepatitis B).
Summary of Infused DMTsDMTHow It’s TakenCommon Side EffectsLemtrada (alemtuzumab)Infused for five days in a row for the first treatment course and then for three days in a row about one year laterHives, itching, sudden redness in the face, neck, or chest, mouth sores, nausea, pain in your arms/legs/back/joints, headache, tingling sensations, dizziness, thyroid problems, urinary tract infection, and fungal infection, plus more common side effects, as statedNovantrone (mitoxantrone)Infused every three monthsNausea, hair loss, menstrual changes upper respiratory infections, urinary tract infections, mouth sores, irregular heartbeat, diarrhea, constipation, back pain, sinusitis, headache, and blue-green urineTyruko, Tysabri (natalizumab)Infused once every four weeksHeadache, feeling tired, urinary tract/lung/nose and throat infections, depression, pain in your joint/arms/legs, diarrhea, nausea, stomach-area pain, vaginitis, and rashOcrevus (ocrelizumab)Infused once every six monthsRelapsing MS: Upper respiratory tract infections and infusion reactionsPPMS: Upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory infectionsBriumvi (ublituximab)Infused once every other week for the first treatment course and then once every six months thereafterUpper and lower respiratory tract infections, infusion reactions, and herpes infectionsIs MS Linked to an Increased Risk for Cancer?SummaryDisease-modifying therapies for multiple sclerosis are medications taken to slow the progression of the condition and delay disability. These medications come in different forms that may be taken orally, injected, or infused. They are indicated for adults with relapsing forms of MS.A Word From VerywellIn the end, starting and sticking to a DMT—even if you have to change drugs along the way—is your best bet for delaying disability and preventing irreversible damage to your central nervous system. That said, navigating the ins and outs of all the DMT options is overwhelming for most.Besides easing stress, the information provided offers a good starting point for discussion when meeting with your neurologist.A Guide to Multiple Sclerosis MedicationsFrequently Asked QuestionsThe American Academy of Neurology recommends considering a DMT if you have clinically isolated syndrome and two or more brain MRIlesions, or if you have relapsing MS and recent relapses or evidence of MRI activity.DMTs slow disease progression. That said, the course of MS varies from person to person. There is no way to definitively predict how fast someone’s MS will progress.
Is MS Linked to an Increased Risk for Cancer?
Summary
Disease-modifying therapies for multiple sclerosis are medications taken to slow the progression of the condition and delay disability. These medications come in different forms that may be taken orally, injected, or infused. They are indicated for adults with relapsing forms of MS.
A Word From Verywell
In the end, starting and sticking to a DMT—even if you have to change drugs along the way—is your best bet for delaying disability and preventing irreversible damage to your central nervous system. That said, navigating the ins and outs of all the DMT options is overwhelming for most.
Besides easing stress, the information provided offers a good starting point for discussion when meeting with your neurologist.
A Guide to Multiple Sclerosis Medications
Frequently Asked QuestionsThe American Academy of Neurology recommends considering a DMT if you have clinically isolated syndrome and two or more brain MRIlesions, or if you have relapsing MS and recent relapses or evidence of MRI activity.DMTs slow disease progression. That said, the course of MS varies from person to person. There is no way to definitively predict how fast someone’s MS will progress.
The American Academy of Neurology recommends considering a DMT if you have clinically isolated syndrome and two or more brain MRIlesions, or if you have relapsing MS and recent relapses or evidence of MRI activity.
DMTs slow disease progression. That said, the course of MS varies from person to person. There is no way to definitively predict how fast someone’s MS will progress.
22 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Rae-Grant A, Day GS, Marrie RA.Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.Neurology.2018;90(17):777-788. doi:10.1212/WNL.0000000000005347McGinley MP, Goldschmidt CH, Rae-Grant AD.Diagnosis and treatment of multiple sclerosis: a review.JAMA.2021;325(8):765-779. doi:10.1001/jama.2020.26858Chalmer TA, Baggesen LM, Nørgaard M et al.Early versus later treatment start in multiple sclerosis: a register-based cohort study.Eur J Neurol.2018;25(10):1262-e110. doi:10.1111/ene.13692National MS Society.Managing relapses in multiple sclerosis.Amatya B, Khan F, Galea M.Rehabilitation for people with multiple sclerosis: An overview of Cochrane Reviews.Cochrane Database Syst Rev.2019;1(1):CD012732. doi:10.1002/14651858.CD012732.pub2National MS Society.Treatments & medications.National Library of Medicine: DailyMed.Gilenya—fingolimod hcl capsule[drug label].Food and Drug Administration.Tascenso ODT label.Food & Drug Administration.FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients.National Library of Medicine: DailyMed.Mayzent—siponimod tablet, film coated[drug label].National Library of Medicine: DailyMed.Zeposia—ozanimod hydrochloride capsule[drug label].National Library of Medicine: DailyMed.Tecfidera—dimethyl fumarate kit[drug label].Burness CB, Deeks ED.Dimethyl fumarate: A review of its use in patients with relapsing-remitting multiple sclerosis.CNS Drugs. 2014;28(4):373-87. doi:10.1007/s40263-014-0155-5National Library of Medicine: DailyMed.Vumerity—diroximel fumarate capsule[drug label].National Library of Medicine: DailyMed.Bafiertam—monomethyl fumarate capsule[drug label].National Library of Medicine: DailyMed.Aubagio—teriflunomide tablet, film coated[drug label].National Library of Medicine: DailyMed.Mavenclad—cladribine tablet[drug label].National Library of Medicine: DailyMed.Lemtrada—alemtuzumab injection, solution, concentrate[drug label].National Library of Medicine: DailyMed.Mitoxantrone—mitoxantrone hydrochloride injection, solution[drug label].National Library of Medicine: DailyMed.Tysabri—natalizumab injection[drug label].National Library of Medicine: DailyMed.Ocrevus—ocrelizumab injection[drug label].National Library of Medicine: DailyMed.Briumvi—ublituximab injection, solution, concentrate[drug label].
22 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Rae-Grant A, Day GS, Marrie RA.Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.Neurology.2018;90(17):777-788. doi:10.1212/WNL.0000000000005347McGinley MP, Goldschmidt CH, Rae-Grant AD.Diagnosis and treatment of multiple sclerosis: a review.JAMA.2021;325(8):765-779. doi:10.1001/jama.2020.26858Chalmer TA, Baggesen LM, Nørgaard M et al.Early versus later treatment start in multiple sclerosis: a register-based cohort study.Eur J Neurol.2018;25(10):1262-e110. doi:10.1111/ene.13692National MS Society.Managing relapses in multiple sclerosis.Amatya B, Khan F, Galea M.Rehabilitation for people with multiple sclerosis: An overview of Cochrane Reviews.Cochrane Database Syst Rev.2019;1(1):CD012732. doi:10.1002/14651858.CD012732.pub2National MS Society.Treatments & medications.National Library of Medicine: DailyMed.Gilenya—fingolimod hcl capsule[drug label].Food and Drug Administration.Tascenso ODT label.Food & Drug Administration.FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients.National Library of Medicine: DailyMed.Mayzent—siponimod tablet, film coated[drug label].National Library of Medicine: DailyMed.Zeposia—ozanimod hydrochloride capsule[drug label].National Library of Medicine: DailyMed.Tecfidera—dimethyl fumarate kit[drug label].Burness CB, Deeks ED.Dimethyl fumarate: A review of its use in patients with relapsing-remitting multiple sclerosis.CNS Drugs. 2014;28(4):373-87. doi:10.1007/s40263-014-0155-5National Library of Medicine: DailyMed.Vumerity—diroximel fumarate capsule[drug label].National Library of Medicine: DailyMed.Bafiertam—monomethyl fumarate capsule[drug label].National Library of Medicine: DailyMed.Aubagio—teriflunomide tablet, film coated[drug label].National Library of Medicine: DailyMed.Mavenclad—cladribine tablet[drug label].National Library of Medicine: DailyMed.Lemtrada—alemtuzumab injection, solution, concentrate[drug label].National Library of Medicine: DailyMed.Mitoxantrone—mitoxantrone hydrochloride injection, solution[drug label].National Library of Medicine: DailyMed.Tysabri—natalizumab injection[drug label].National Library of Medicine: DailyMed.Ocrevus—ocrelizumab injection[drug label].National Library of Medicine: DailyMed.Briumvi—ublituximab injection, solution, concentrate[drug label].
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Rae-Grant A, Day GS, Marrie RA.Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.Neurology.2018;90(17):777-788. doi:10.1212/WNL.0000000000005347McGinley MP, Goldschmidt CH, Rae-Grant AD.Diagnosis and treatment of multiple sclerosis: a review.JAMA.2021;325(8):765-779. doi:10.1001/jama.2020.26858Chalmer TA, Baggesen LM, Nørgaard M et al.Early versus later treatment start in multiple sclerosis: a register-based cohort study.Eur J Neurol.2018;25(10):1262-e110. doi:10.1111/ene.13692National MS Society.Managing relapses in multiple sclerosis.Amatya B, Khan F, Galea M.Rehabilitation for people with multiple sclerosis: An overview of Cochrane Reviews.Cochrane Database Syst Rev.2019;1(1):CD012732. doi:10.1002/14651858.CD012732.pub2National MS Society.Treatments & medications.National Library of Medicine: DailyMed.Gilenya—fingolimod hcl capsule[drug label].Food and Drug Administration.Tascenso ODT label.Food & Drug Administration.FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients.National Library of Medicine: DailyMed.Mayzent—siponimod tablet, film coated[drug label].National Library of Medicine: DailyMed.Zeposia—ozanimod hydrochloride capsule[drug label].National Library of Medicine: DailyMed.Tecfidera—dimethyl fumarate kit[drug label].Burness CB, Deeks ED.Dimethyl fumarate: A review of its use in patients with relapsing-remitting multiple sclerosis.CNS Drugs. 2014;28(4):373-87. doi:10.1007/s40263-014-0155-5National Library of Medicine: DailyMed.Vumerity—diroximel fumarate capsule[drug label].National Library of Medicine: DailyMed.Bafiertam—monomethyl fumarate capsule[drug label].National Library of Medicine: DailyMed.Aubagio—teriflunomide tablet, film coated[drug label].National Library of Medicine: DailyMed.Mavenclad—cladribine tablet[drug label].National Library of Medicine: DailyMed.Lemtrada—alemtuzumab injection, solution, concentrate[drug label].National Library of Medicine: DailyMed.Mitoxantrone—mitoxantrone hydrochloride injection, solution[drug label].National Library of Medicine: DailyMed.Tysabri—natalizumab injection[drug label].National Library of Medicine: DailyMed.Ocrevus—ocrelizumab injection[drug label].National Library of Medicine: DailyMed.Briumvi—ublituximab injection, solution, concentrate[drug label].
Rae-Grant A, Day GS, Marrie RA.Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.Neurology.2018;90(17):777-788. doi:10.1212/WNL.0000000000005347
McGinley MP, Goldschmidt CH, Rae-Grant AD.Diagnosis and treatment of multiple sclerosis: a review.JAMA.2021;325(8):765-779. doi:10.1001/jama.2020.26858
Chalmer TA, Baggesen LM, Nørgaard M et al.Early versus later treatment start in multiple sclerosis: a register-based cohort study.Eur J Neurol.2018;25(10):1262-e110. doi:10.1111/ene.13692
National MS Society.Managing relapses in multiple sclerosis.
Amatya B, Khan F, Galea M.Rehabilitation for people with multiple sclerosis: An overview of Cochrane Reviews.Cochrane Database Syst Rev.2019;1(1):CD012732. doi:10.1002/14651858.CD012732.pub2
National MS Society.Treatments & medications.
National Library of Medicine: DailyMed.Gilenya—fingolimod hcl capsule[drug label].
Food and Drug Administration.Tascenso ODT label.
Food & Drug Administration.FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients.
National Library of Medicine: DailyMed.Mayzent—siponimod tablet, film coated[drug label].
National Library of Medicine: DailyMed.Zeposia—ozanimod hydrochloride capsule[drug label].
National Library of Medicine: DailyMed.Tecfidera—dimethyl fumarate kit[drug label].
Burness CB, Deeks ED.Dimethyl fumarate: A review of its use in patients with relapsing-remitting multiple sclerosis.CNS Drugs. 2014;28(4):373-87. doi:10.1007/s40263-014-0155-5
National Library of Medicine: DailyMed.Vumerity—diroximel fumarate capsule[drug label].
National Library of Medicine: DailyMed.Bafiertam—monomethyl fumarate capsule[drug label].
National Library of Medicine: DailyMed.Aubagio—teriflunomide tablet, film coated[drug label].
National Library of Medicine: DailyMed.Mavenclad—cladribine tablet[drug label].
National Library of Medicine: DailyMed.Lemtrada—alemtuzumab injection, solution, concentrate[drug label].
National Library of Medicine: DailyMed.Mitoxantrone—mitoxantrone hydrochloride injection, solution[drug label].
National Library of Medicine: DailyMed.Tysabri—natalizumab injection[drug label].
National Library of Medicine: DailyMed.Ocrevus—ocrelizumab injection[drug label].
National Library of Medicine: DailyMed.Briumvi—ublituximab injection, solution, concentrate[drug label].
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.Cookies SettingsAccept All Cookies
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies SettingsAccept All Cookies
